Tagged with Exclusiv

Pharma GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at GE Healthcare for 18 years now, having risen up the ranks through various departments. What was at the top of…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you most busy in recent months? We have, for the third consecutive year, topped IDEA Pharma’s Productive Innovation Index (PII), which…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…

Pharma Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first oral, non-estrogenic drug in the field of vulvar and vaginal atrophy, and the central role of partnerships in the company’s…

Pharma Bernard Fraisse of Fareva, France’s leading CMO, discusses growth, international expansion, loyalty to France, dedication to clients, and commitment to providing high quality products. Many have predicted that pharma manufacturing in France will soon die out, but instead we have seen a shift from manufacturing of large pharmaceutical groups to…

Pharma The chairman of the committee on health and social policy of the Czech Senate names the role that health insurance companies inherit and the transparency of the healthcare system as aspects in need of reform, while highlighting that the system overall is effective and stable. He also elaborates on how…

Pharma Outspoken Italian Managing Director of Israeli-based Teva, Hubert Puech d’Alissac, talks about his passion for social responsibility, adapting to the new realities of patient care in the digital age, and his aspirations for the “Made in Italy” brand. When we covered Italy in 2009 your predecessor Mr. Walter Medda spoke…

Pharma Marc Alexander Burmeister of B. Braun France speaks about the country’s role as a production hub for B. Braun’s global operations, its 2020 strategy to reach USD 200 million in investments, and the French affiliate’s growth through acquisition of SMEs. The B. Braun Group recently shared its Strategy 2020 in…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…

Pharma The traditional model of healthcare has generally been limited to treatment in health facilities. But, when it comes to effectively treating more private and deeply personal health conditions, especially in South Africa, companies such as Coloplast have untaken substantial efforts to partner hand-in-hand with patients through support programs that focus…

Pharma Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However, without the presence of proper mechanisms to arbitrate between regulators and researchers, the sustained growth of this industry may very…